CL
NVCR icon

Choreo LLC’s NovoCure NVCR Stock Holding History

Choreo LLC’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,545
Closed -$136K – 1635
2025
Q3 		$136K Sell
10,545
-4,702
-31% -$62.8K ﹤0.01% 1496
2025
Q2 		$271K Buy
15,247
+1,994
+15% +$34.7K ﹤0.01% 1242
2025
Q1 		$236K Buy
13,253
+4,903
+59% +$111K ﹤0.01% 1229
2024
Q4 		$251K Buy
+8,350
New +$177K ﹤0.01% 1282
2024
Q3 		– Sell
-11,131
Closed -$192K – 1659
2024
Q2 		$192K Buy
+11,131
New +$196K ﹤0.01% 1346

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Choreo LLC's NVCR Position: Q4 2025 in Review

Choreo LLC sold out of NovoCure (NVCR) in Q4 2025, closing a stake of 10,545 shares — an estimated $136K sold.

Choreo LLC first reported a position in NVCR in Q2 2024 and held it in 5 quarters. The position peaked at $271K in Q2 2025. 238 funds tracked by Wall St. Rank hold NVCR as of Q4 2025.

  • Choreo LLC reported no remaining NovoCure position as of Q4 2025 after selling out during the quarter.
  • Choreo LLC sold 10,545 NovoCure shares in Q4 2025, an estimated $136K.
  • Choreo LLC first reported a position in NovoCure in Q2 2024 and held it in 5 quarters.
  • Choreo LLC's NovoCure position peaked at $271K in Q2 2025.
  • 238 funds tracked by Wall St. Rank held NovoCure as of Q4 2025.

Based on Choreo LLC's 13F filing for Q4 2025, filed 23 Jan 2026.